Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

MLA

Arnon P. Kater, et al. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Dec. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8c0bf03b36363e802b1b13954f0a6180&authtype=sso&custid=ns315887.

APA

Arnon P. Kater, Kathryn Humphrey, Tong Lu, Michelle Boyer, Ahmed Salem, Smita Kshirsagar, Leonid Gibiansky, John F. Seymour, Hao Ding, Dale Miles, Xiaobin Li, Jue Wang, Kevin J. Freise, Sandhya Girish, Rong Deng, Priya Agarwal, Chunze Li, & Dan Lu. (2019). Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.

Chicago

Arnon P. Kater, Kathryn Humphrey, Tong Lu, Michelle Boyer, Ahmed Salem, Smita Kshirsagar, Leonid Gibiansky, et al. 2019. “Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8c0bf03b36363e802b1b13954f0a6180&authtype=sso&custid=ns315887.